

Corey S Cutler

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1786416/corey-s-cutler-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261
papers

17,596
citations

69
h-index

130
g-index

278
ext. papers

20,724
ext. citations

4.4
avg, IF

5.96
L-index

#	Paper	IF	Citations
261	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 389-401.e1	4.7	1187
260	Interleukin-2 and regulatory T cells in graft-versus-host disease. <i>New England Journal of Medicine</i> , 2011 , 365, 2055-66	59.2	787
259	Peripheral-blood stem cells versus bone marrow from unrelated donors. <i>New England Journal of Medicine</i> , 2012 , 367, 1487-96	59.2	620
258	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. <i>Blood</i> , 2004 , 104, 579-85	2.2	535
257	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011 , 118, 282-8	2.2	476
256	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. <i>Blood</i> , 2012 , 119, 296-307	3.07	416
255	First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1150-63	4.7	399
254	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017 , 376, 536-547	59.2	383
253	Rituximab for steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2006 , 108, 756-62	2.2	378
252	Ipilimumab for Patients with Relapse after Allogeneic Transplantation. <i>New England Journal of Medicine</i> , 2016 , 375, 143-53	59.2	365
251	Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3685-91	2.2	359
250	Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. <i>Blood</i> , 2007 , 109, 4586-8	2.2	349
249	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. <i>Blood</i> , 2005 , 105, 2973-8	2.2	315
248	Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. <i>Science Translational Medicine</i> , 2013 , 5, 179ra43	17.5	312
247	Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2691-8	2.2	295
246	Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2003 , 102, 1578-82	2.2	270
245	Double unrelated reduced-intensity umbilical cord blood transplantation in adults. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 82-9	4.7	264

244	Skin effector memory T cells do not recirculate and provide immune protection in alemtuzumab-treated CTCL patients. <i>Science Translational Medicine</i> , 2012 , 4, 117ra7	17.5	260
243	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012 , 120, 905-13	2.2	259
242	Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. <i>Blood</i> , 2013 , 122, 3074-81	2.2	252
241	Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. <i>Blood</i> , 2011 , 117, 4651-7	2.2	251
240	Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. <i>Blood</i> , 2005 , 105, 1810-4	2.2	247
239	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. <i>Blood</i> , 2009 , 113, 3865-74	2.2	236
238	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017 , 130, 2243-2250	2.2	220
237	Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 266-74	4.7	214
236	Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2662-70	2.2	203
235	High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. <i>Clinical Cancer Research</i> , 2007 , 13, 6107-14	12.9	190
234	Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. <i>Blood</i> , 2017 , 129, 1753-1762	2.2	189
233	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010 , 120, 1479-93	15.9	175
232	Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. <i>Blood</i> , 2004 , 104, 1559-64	2.2	170
231	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011 , 118, 4242-9	2.2	169
230	Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. <i>Blood</i> , 2007 , 109, 3108-14	2.2	163
229	Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1047-55	4.7	161
228	Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. <i>Blood</i> , 2011 , 118, 6691-7	2.2	153
227	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014 , 123, 3988-98	2.2	144

226	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014 , 124, 1372-7	2.2	142
225	Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. <i>Blood</i> , 2003 , 102, 1601-5	2.2	140
224	Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. <i>Blood</i> , 2008 , 112, 4425-31	2.2	139
223	Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 551-7	4.7	133
222	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014 , 124, 4867-76	15.9	132
221	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016 , 128, 130-7	2.2	132
220	Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1262-73	4.7	130
219	Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 104, 1224-6	2.2	128
218	Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 328-36	4.7	124
217	Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. <i>Blood</i> , 2007 , 110, 490-500	2.2	119
216	Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3202-8	2.2	115
215	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017 , 129, 2186-2197	2.2	109
214	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016 , 127, 646-57	2.2	109
213	Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1796-803	4.7	108
212	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011 , 117, 6714-20	2.2	105
211	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011 , 117, 2275-83	2.2	101
210	Efficacy of rituximab in the setting of steroid-refractory chronic graft-versus-host disease: a systematic review and meta-analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1005-13	4.7	101
209	B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. <i>Blood</i> , 2012 , 120, 2529-36	2.2	98

208	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. <i>Blood</i> , 2016 , 127, 2144-54	2.2	94
207	Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. <i>Blood</i> , 2013 , 122, 1510-7	2.2	93
206	Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5767-74	2.2	92
205	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012 , 120, 2545-52; quiz 2774	2.2	91
204	Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 383-8	4.7	89
203	Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 552-9	4.7	89
202	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2583-90	2.2	88
201	Low-dose IL-2 selectively activates subsets of CD4 Tregs and NK cells. <i>JCI Insight</i> , 2016 , 1, e89278	9.9	87
200	Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 197-207	4.7	82
199	Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 852-60	4.7	80
198	Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1583-1589	13.4	78
197	Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 882-896	4.7	77
196	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015 , 125, 4085-94	2.2	76
195	Peripheral blood stem cells for allogeneic transplantation: a review. <i>Stem Cells</i> , 2001 , 19, 108-17	5.8	74
194	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016 , 127, 2489-97	2.2	71
193	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 449-55	4.7	71
192	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1343-59	4.7	69
191	Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). <i>Blood</i> , 2013 , 122, 1974-82	2.2	69

190	Prediction of veno-occlusive disease using biomarkers of endothelial injury. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1180-5	4.7	69
189	Mechanistic approaches for the prevention and treatment of chronic GVHD. <i>Blood</i> , 2017 , 129, 22-29	2.2	68
188	Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 792-800	4.7	68
187	B cells in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 16-23	4.7	63
186	Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. <i>Blood</i> , 2018 , 131, 1372-1379	2.2	59
185	Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. <i>British Journal of Haematology</i> , 2009 , 145, 816-24	4.5	59
184	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. <i>Blood</i> , 2017 , 129, 162-170	2.2	56
183	Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1196-204	4.7	51
182	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017 , 102, 958-966	6.6	50
181	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019 , 3, 1826-1836	7.8	50
180	Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 844-50	4.7	47
179	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1864-71	2.2	46
178	Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 920-6	4.7	44
177	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016 , 173, 96-104	4.5	43
176	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. <i>JCI Insight</i> , 2017 , 2,	9.9	40
175	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017 , 130, 360-367	2.2	39
174	Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 873-80	4.7	38
173	Clinical benefit of response in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1517-24	4.7	38

172	A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1737-43	4.7	37
171	Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, S18-27	4.7	36
170	Donor-derived second hematologic malignancies after cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1025-31	4.7	35
169	Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. <i>Current Opinion in Hematology</i> , 2010 , 17, 500-4	3.3	35
168	Chronic graft-versus-host disease. <i>Current Opinion in Oncology</i> , 2006 , 18, 126-31	4.2	35
167	Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. <i>Blood</i> , 2011 , 118, 5021-30	2.2	34
166	Current and novel therapies in acute GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2008 , 21, 223-37	4.2	34
165	Rituximab for prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011 , 93, 578-585	2.3	33
164	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016 , 128, 2350-2358	2.2	33
163	Machine learning reveals chronic graft--host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. <i>Haematologica</i> , 2019 , 104, 189-196	6.6	33
162	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2002-2007	4.7	32
161	Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. <i>Therapeutic Advances in Hematology</i> , 2012 , 3, 253-65	5.7	32
160	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016 , 122, 3005-3014	6.4	32
159	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020 , 135, 2182-2191	2.2	31
158	Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 668-75	4.7	29
157	Improving outcomes in umbilical cord blood transplantation: state of the art. <i>Blood Reviews</i> , 2012 , 26, 241-6	11.1	29
156	High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. <i>Transfusion</i> , 2009 , 49, 995-1002	2.9	29
155	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 137-144	4.7	27

154	Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 202-8	4.7	27
153	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2016 , 101, 499-505	6.6	26
152	A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1907-13	4.7	25
151	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021 , 138, 2278-2289	2.2	24
150	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019 , 3, 2199-2204	7.8	24
149	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020 , 4, 1965-1973	7.3	23
148	An overview of hematopoietic stem cell transplantation. <i>Clinics in Chest Medicine</i> , 2005 , 26, 517-27, v	5.3	23
147	Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 640-5	4.7	21
146	A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018 , 103, 1915-1924	6.6	21
145	Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1649-55	4.7	21
144	Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. <i>Journal of Clinical Oncology</i> , 2011 , 29, 566-72	2.2	21
143	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 910-8	4.7	19
142	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2344-2353	4.7	19
141	Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. <i>JAMA Oncology</i> , 2020 , 6, 486-493	13.4	19
140	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019 , 3, 2550-2561	7.8	19
139	Venous thromboembolism is associated with graft-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017 , 102, 1185-1191	6.6	18
138	Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1007-1013	4.7	18
137	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4624-4636	15.9	18

136	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 393-399	4.7	17
135	Allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 325-9	3.1	17
134	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016 , 101, 1251-1259	6.6	17
133	Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Blood Advances</i> , 2019 , 3, 4136-4146	7.8	17
132	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018 , 2, 1882-1888	7.8	16
131	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. <i>Blood Advances</i> , 2017 , 1, 2269-2279	7.8	15
130	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015 , 10, e0132564	3.7	15
129	Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. <i>Blood Advances</i> , 2019 , 3, 969-979	7.8	15
128	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 599-605	4.7	15
127	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021 , 5, 352-364	7.8	15
126	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 545-557		15
125	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014 , 99, 1499-508	6.6	14
124	Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3328-3339	2.2	14
123	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019 , 133, 94-99	2.2	14
122	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. <i>Cytotherapy</i> , 2017 , 19, 272-284	4.8	13
121	Mammalian target of rapamycin inhibitor-associated stomatitis in hematopoietic stem cell transplantation patients receiving sirolimus prophylaxis for graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 503-8	4.7	13
120	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017 , 130, 2889-2899	2.2	13
119	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015 , 100, 1222-7	6.6	13

118	Novel drugs for the prevention and treatment of acute GVHD. <i>Current Pharmaceutical Design</i> , 2008 , 14, 1962-73	3.3	13
117	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. <i>Blood</i> , 2011 , 118, 115-115	2.2	13
116	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 4113-4123	7.8	13
115	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , 2020 , 136, 3070-3081	2.2	13
114	Outcomes after Umbilical Cord Blood Transplantation for Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 971-979	4.7	11
113	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network [BMTCTN0100]). <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2143-2151	4.7	11
112	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1776-82	4.7	11
111	Generic immunosuppressants in hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 285-90	4.7	11
110	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021 , 5, 861-871	7.8	11
109	A multicenter, retrospective, case-cohort study of the epidemiology and risk factors for <i>Clostridium difficile</i> infection among cord blood transplant recipients. <i>Transplant Infectious Disease</i> , 2017 , 19, e12728	2.7	10
108	Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 804-11	4.7	10
107	Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age. <i>Blood</i> , 2015 , 126, 193-193	2.2	10
106	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 451-458	4.7	10
105	Manifestations and Treatment of Acute Graft-Versus-Host Disease		10
104	Outcomes and management strategies for graft failure after umbilical cord blood transplantation. <i>American Journal of Hematology</i> , 2014 , 89, 1097-101	7.1	9
103	Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 126-133	4.7	9
102	A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018 , 132, 705-705	2.2	9
101	Disability Related to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 772-777	4.7	9

100	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021 , 137, 3212-3217	2.2	9
99	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2084-2091	4.7	8
98	Targeting PI3K function for amelioration of murine chronic graft-versus-host disease. <i>American Journal of Transplantation</i> , 2019 , 19, 1820-1830	8.7	8
97	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. <i>Blood</i> , 2020 , 135, 28-40	2.2	8
96	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018 , 2, 1022-1031	7.8	8
95	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020 , 4, 1881-1893	7.8	7
94	GVHD prevention: an ounce is better than a pound. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, S17-26	4.7	7
93	Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213). <i>Blood</i> , 2020 , 136, 45-46	2.2	7
92	Incidence, Predictors, and Outcomes of Venous Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 529-539	4.7	7
91	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 452-466		7
90	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021 , 106, 3219-3222	6.6	7
89	Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1748-1753	4.7	6
88	Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia. <i>Hematology American Society of Hematology Education Program</i> , 2014 , 2014, 77-81	3.1	6
87	Patient selection for transplantation in the myelodysplastic syndromes. <i>Hematology/Oncology Clinics of North America</i> , 2010 , 24, 469-76	3.1	6
86	Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way. <i>Journal of Clinical Oncology</i> , 2002 , 20, 603-6	2.2	6
85	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 632-641		6
84	Transplantation for MDS in the elderly: more evidence, or more bias?. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1320-1	4.7	5
83	Manifestations and Treatment of Acute Graft-versus-Host Disease 2016 , 1012-1025		5

82	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1006-1012	4.4	5
81	Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021 , 5, 975-983	7.8	5
80	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 729-737		5
79	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 817-835		5
78	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2468-2473	4.7	4
77	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4 and CD8 T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019 , 207, 18-23	9	4
76	Reprint of: B cells in chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S11-8	4.7	4
75	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020 , 4, 3180-3190	7.8	4
74	The clinical and functional effects of TERT variants in myelodysplastic syndrome. <i>Blood</i> , 2021 , 138, 898-911	9.1	4
73	A novel TERC CR4/CR5 domain mutation causes telomere disease via decreased TERT binding. <i>Blood</i> , 2016 , 128, 2089-2092	2.2	4
72	The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 279-286	4.7	4
71	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 103-112	4.7	3
70	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. <i>Blood</i> , 2004 , 104, 351-351	2.2	3
69	Sirolimus, Tacrolimus and Reduced-Dose Methotrexate as Graft Versus Host Disease (GVHD) Prophylaxis after Non-Myeloablative Stem Cell Transplantation: Low Incidence of Acute GVHD Compared with Tacrolimus/Methotrexate or Cyclosporine/Prednisone.. <i>Blood</i> , 2004 , 104, 730-730	2.2	3
68	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 835-835	2.2	3
67	A positive psychology intervention to promote health outcomes in hematopoietic stem cell transplantation: the PATH proof-of-concept trial. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2276-2279	4.4	3
66	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2164-2165	4.7	3
65	Choroidal metastases. Case 2: lung cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3358-9	2.2	2

64	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. <i>Blood</i> , 2004 , 104, 2251-2251	2.2	2
63	Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 595-595	2.2	2
62	Long-Term Utilization Patterns of Topical Therapy and Clinical Outcomes of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 373-379	4.7	2
61	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021 , 35, 1166-1175	10.7	2
60	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. <i>Blood Advances</i> , 2021 , 5, 5140-5149	7.8	2
59	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021 , 5, 4278-4284	7.8	2
58	In response to "American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults". <i>Blood Advances</i> , 2020 , 4, 5431-5432	7.8	1
57	Oral health in allogeneic hematopoietic stem cells transplantation survivors. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2211-2214	4.4	1
56	The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era. <i>Current Hematologic Malignancy Reports</i> , 2006 , 1, 160-7	4.4	1
55	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). <i>Blood</i> , 2018 , 132, 2110-2110	2.2	1
54	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004 , 104, 1834-1834	2.2	1
53	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. <i>Blood</i> , 2006 , 108, 259-259	2.2	1
52	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. <i>Blood</i> , 2006 , 108, 2929-2929	2.2	1
51	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).. <i>Blood</i> , 2006 , 108, 3148-3148	2.2	1
50	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2006 , 108, 3680-3680	2.2	1
49	Prior Therapy with Rituximab Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-Cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2007 , 110, 1063-1063	2.2	1
48	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007 , 110, 166-166		1
47	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. <i>Blood</i> , 2007 , 110, 2016-2016	2.2	1

46	Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).. <i>Blood</i> , 2007 , 110, 3046-3046	2.2	1
45	Detection of Recurrent Mutations by Pooled Targeted Next-Generation Sequencing in MDS Patients Prior to Treatment with Hypomethylating Agents or Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 311-311	2.2	1
44	Impact Of Umbilical Cord Unit Banking Conditions On Clinical Outcomes In Double Cord Transplant Recipients. <i>Blood</i> , 2013 , 122, 695-695	2.2	1
43	Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?. <i>Blood</i> , 2015 , 126, 3132-3132	2.2	1
42	Stem Cell Sources 2004 , 337-356		1
41	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2108-2117	4.4	1
40	Use of Prescription Sialogogues for Management of Xerostomia in Chronic Graft-versus-Host-Disease. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 480.e1-480.e5		1
39	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021 , 5, 4549-4559	7.8	1
38	Disseminated varicella-zoster virus infections following messenger RNA-based COVID-19 vaccination. <i>JAAD Case Reports</i> , 2021 , 17, 126-129	1.4	1
37	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2021 , 138, 264-264	2.2	0
36	Topical sirolimus for management of refractory oral chronic graft-versus-host disease. <i>Oral Diseases</i> , 2021 , 27, 1451-1454	3.5	0
35	Yin and Yang of Psychological Health in the Cancer Experience: Does Positive Psychology Have a Role?. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102507	2.2	0
34	Reply to J. Mehta. <i>Journal of Clinical Oncology</i> , 2009 , 27, e139-e140	2.2	
33	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. <i>Blood</i> , 2020 , 136, 10-11	2.2	
32	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2020 , 136, 2-3	2.2	
31	Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease. <i>Blood</i> , 2021 , 138, 2891-2891	2.2	
30	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. <i>Blood</i> , 2004 , 104, 1227-1227	2.2	
29	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. <i>Blood</i> , 2004 , 104, 185-185	2.2	

28	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. <i>Blood</i> , 2004 , 104, 296-296	2.2
27	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. <i>Blood</i> , 2004 , 104, 300-300	2.2
26	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. <i>Blood</i> , 2004 , 104, 3317-3317	2.2
25	Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.. <i>Blood</i> , 2005 , 106, 2051-2051	2.2
24	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2005 , 106, 1797-1797	2.2
23	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. <i>Blood</i> , 2006 , 108, 2977-2977	
22	Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. <i>Blood</i> , 2006 , 108, 757-757	2.2
21	Non-Myeloablative Allogeneic Transplantation for Hodgkin \bar{B} and Non-Hodgkin \bar{B} Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. <i>Blood</i> , 2007 , 110, 3041-3041 ^{2,2}	
20	Stem Cell Sources for Allogeneic Transplantation 2008 , 225-244	
19	Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018 , 132, 3376-3376	2.2
18	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018 , 132, 817-817	2.2
17	Phase I Multicenter Trial of Brentuximab Vedotin for Steroid Refractory Acute Graft-Vs.-Host Disease (GVHD). <i>Blood</i> , 2015 , 126, 1930-1930	2.2
16	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. <i>Blood</i> , 2016 , 128, 63-63	2.2
15	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016 , 128, 508-508	2.2
14	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 3425-3425	2.2
13	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016 , 128, 667-667	2.2
12	Development of CMV-SPECIFIC Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of NAI VE CD8+ T Cells. <i>Blood</i> , 2008 , 112, 1167-1167 ^{2,2}	
11	Acute Graft Versus Host Disease: Prophylaxis 2010 , 565-576	

- 10 Does Iron Overload Really Matter in Stem Cell Transplantation?. *Blood*, **2011**, 118, 3029-3029 2.2
- 9 A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. *Blood*, **2011**, 118, 327-327 2.2
- 8 Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. *Blood*, **2012**, 120, 1940-1940 2.2
- 7 Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). *Blood*, **2012**, 120, 1892-1892 2.2
- 6 Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. *Blood*, **2012**, 120, 3069-3069 2.2
- 5 Oral Complications in Hematopoietic Stem Cell Transplantation Survivorship 172-182
- 4 Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intensity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A CIBMTR Analysis. *Blood*, **2013**, 122, 2093-2093 2.2
- 3 Reconstitution Of EBV-Specific Immunity In Adult Recipients Of Double Cord Blood Transplantation Depends On SCF and IL-7 Levels and Maintenance Of a Diverse TCR Repertoire. *Blood*, **2013**, 122, 3302-3302 2.2
- 2 Treating Inflammation and Fibrosis in Chronic GVHD: Two Birds, One ROCK. *Journal of Clinical Oncology*, **2021**, 39, 1942-1945 2.2
- 1 A Review of Oral Chronic Graft-Versus-Host Disease: Considerations for dental hygiene practice.. *Journal of Dental Hygiene: JDH / American Dental Hygienists Association*, **2022**, 96, 6-17 1.1